Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Vertex Pharmaceuticals Q1 2026 Earnings Call - Povi IgAN Data Sparks Renal Franchise Ambitions
Vertex Pharmaceuticals delivered a strong Q1 2026, with revenue rising 8% to $2.99 billion, driven by steady CF growth and early contributions from CASGEVY and JOURNAVX. The company's strategic pivot ...
- Q1 2026 total revenue reached $2.99 billion, an 8% year-over-year increase, with CF revenue growing 6% and new disease areas (CASGEVY and JOURNAVX) contributing approximately 25% of total growth.
- Povi (povetacicept) demonstrated 'sparkling' interim Phase III data in IgAN, achieving a 52% reduction in proteinuria and a 77.4% reduction in serum Gd-IgA1 levels, with a favorable safety profile showing no opportunistic infections.
- Vertex submitted the Biologics License Application (BLA) for Povi in IgAN just 27 days after database lock, marking the fastest regulatory submission in the company's history.
- +7 more takeaways
Allison Transmission Q1 2026 Earnings Call - Synergy Realization Begins as Defense and Mining Drive Growth
Allison Transmission reported a solid first quarter despite macroeconomic headwinds, with Adjusted EBITDA rising 22% year-over-year and adjusted EPS up 6%. The company’s acquisition of Dana Off-Highwa...
- Adjusted EBITDA rose 22% year-over-year to $362 million, with margins holding at 26% despite acquisition-related costs.
- Adjusted diluted EPS increased 6% to $2.57, excluding non-recurring acquisition expenses.
- Defense revenue jumped 64% year-over-year, driven by strong international demand for new transmission programs.
- +7 more takeaways
Advanced Energy Q1 2026 Earnings Call - Margin Breaks 40% as Data Center and Semiconductor Demand Accelerates
Advanced Energy delivered a standout first quarter, with revenue jumping 26% year-over-year to $511 million and gross margin cracking the 40% threshold for the first time since the Artesyn acquisition...
- Revenue surged 26% year-over-year to $511 million, beating the midpoint of guidance, driven by record data center revenue.
- Gross margin exceeded 40% for the first time since the Artesyn acquisition, reflecting improved product mix, manufacturing efficiency, and lower cost of sales.
- Data center computing revenue hit a record $194 million, up 102% year-over-year, with management raising full-year growth expectations to the mid-30% range.
- +7 more takeaways
REPAY Holdings Inc Q1 2026 Earnings Call - KUBRA Acquisition Doubles Scale and Drives Margin Expansion
REPAY Holdings delivered a solid Q1 2026, posting $80.8 million in revenue and a 4% year-over-year increase, while maintaining an impressive 43% Adjusted EBITDA margin. Management raised its full-year...
- REPAY reported Q1 2026 revenue of $80.8 million, up 4% year-over-year, with Consumer Payments growing 4% and Business Payments surging 18% year-over-year.
- Management raised its full-year 2026 Adjusted EBITDA margin outlook to approximately 42%, citing immediate accretion from a strategic distribution partner investment and volume routing optimizations.
- The company is aggressively pursuing the acquisition of KUBRA, which it believes will double its revenue, process over $130 billion in annual payment volumes, and create a comprehensive end-to-end digital platform.
- +7 more takeaways
V2X Q1 2026 Earnings Call - Record Backlog and Raised Guidance Signal Sustained Defense Demand
V2X delivered a record-breaking first quarter in 2026, with revenue surging 23% year-over-year to $1.25 billion and adjusted diluted EPS jumping 55% to $1.53. The company secured approximately $4.1 bi...
- Revenue surged 23% year-over-year to $1.25 billion, marking a record organic growth rate for V2X.
- Adjusted diluted EPS jumped 55% year-over-year to $1.53, outpacing revenue growth due to margin expansion.
- New contract awards totaled approximately $4.1 billion, including a major T-6 training program win, driving a 3.2x book-to-bill ratio.
- +7 more takeaways
Cryoport {Q1} 2026 Earnings Call - Raising Full-Year Guidance on Double-Digit Growth
Cryoport delivered a forceful start to 2026, reporting 16% year-over-year revenue growth to $47.8 million and raising its full-year guidance. The company’s integrated platform is working. Life Science...
- Full-year 2026 revenue guidance raised to $192 million - $196 million, reflecting strong early-year momentum and increased visibility.
- First-quarter revenue reached $47.8 million, a 16% year-over-year increase, driven by robust performance across both reporting segments.
- Life Sciences Services revenue grew 18% year-over-year, with BioStorage Bioservices leading the charge at 21% growth.
- +7 more takeaways
BioMarin Pharmaceutical Inc Q1 2026 Earnings Call - Amicus Acquisition Closes, 2026 Revenue Guidance Raised to $3.825B
BioMarin has officially closed its acquisition of Amicus, injecting high-growth enzyme therapies like Galafold and Pombiliti/Opfolda into its portfolio and immediately driving a 20% growth trajectory ...
- Amicus Acquisition Closed: BioMarin successfully closed its acquisition of Amicus last week, adding Galafold (Fabry disease) and Pombiliti/Opfolda (Pompe disease) to its commercial portfolio.
- Raised 2026 Revenue Guidance: Full-year 2026 revenue guidance is raised to $3.825 billion-$3.925 billion, reflecting a 20% year-over-year growth midpoint.
- Enzyme Therapies Growth: Enzyme therapies revenue guidance is raised to $2.725 billion-$2.775 billion, driven by a 30% growth midpoint after integrating Amicus assets.
- +9 more takeaways
Adeia Q1 2026 Earnings Call - New Customers AMD and Microsoft Drive Semiconductor and Media Growth
Adeia delivered a strong start to 2026 with first-quarter revenue of $105 million and an adjusted EBITDA margin of 60%. The company closed eight license agreements, highlighted by foundational multi-y...
- Adeia reported Q1 2026 revenue of $105 million, driven by eight new license agreements across semiconductors, media, e-commerce, and consumer electronics.
- New multi-year agreements with AMD (semiconductors) and Microsoft (media) mark a strategic expansion beyond traditional pay TV licensing.
- Non-pay TV recurring revenue grew 28% year-over-year, signaling successful diversification into high-growth technology sectors.
- +7 more takeaways
Ameresco {Q1} {2026} Earnings Call - Transformative Neogenyx JV Unlocks $1.8B Biofuels Value While Core Business Posts 14% Revenue Growth
Ameresco delivered a 14% year-over-year revenue increase in Q1 2026, driven by strong project execution and resilient demand in federal and building efficiency markets. The quarter was marked by a tra...
- Ameresco reported Q1 2026 revenue of $401 million, up 14% year-over-year, with project revenue leading at $291 million (up 16%) and O&M revenue surging 22% to reflect long-term contract additions.
- Awarded project backlog grew 20% to $2.8 billion, bringing total project backlog to $5.3 billion, signaling strong demand in federal modernization, building efficiency, and energy infrastructure.
- Ameresco signed a $400 million strategic investment agreement with HASI to form Neogenyx Fuels, a 70/30 joint venture that monetizes the biofuels platform at an implied $1.8 billion enterprise value.
- +7 more takeaways
ThredUp Q1 2026 Earnings Call - AI-Driven Personalization and Supply Surge Outpace Macro Headwinds
ThredUp delivered a strong Q1 2026, with revenue up 14.6% to $81.7 million and active buyers growing 25% year-over-year. The company is navigating a discerning consumer environment, marked by a 3% dec...
- Revenue grew 14.6% year-over-year to $81.7 million, outpacing internal expectations and signaling sustained demand in the secondhand market.
- Active buyers surged 25% year-over-year to 1.7 million, with March marking the best acquisition month in the company's history.
- Gross margin expanded 10 basis points to 79.2%, while Adjusted EBITDA reached $2.7 million (3.4% of revenue), beating management's internal targets.
- +7 more takeaways